No Data
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $145
Wells Fargo Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Express News | Merck & Co Inc - FDA Reviewing Ifinatamab Deruxtecan Bla Under Rtor and Project Orbis Programs
Express News | Merck & Co Inc: Prescription Drug User Fee Act (Pdufa) Date, FDA Action Date for Its Regulatory Decision, Is October 10
Express News | Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression on or After Platinum-Based Chemotherapy